Clinical Trial Update: Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions [Phase 3]

View source ↗

Summary

A Phase 3 trial update evaluating Gardasil-9 as secondary prevention for HPV-related HSIL at multiple anogenital sites. The study is currently not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-related High-grade Squamous Intraepithelial Lesion of the Anus
• Hpv-related High-grade Squamous Intraepithelial Lesion of the Cervix
• Hpv-related High-grade Squamous Intraepithelial Lesion of the Penis
• Hpv-related High-grade Squamous Intraepithelial Lesion of the Vagina
• Hpv-related High-grade Squamous Intraepithelial Lesion of the Vulva

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vulvar Site, Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vaginal Site | Phase 3 | Status: NOT_YET_RECRUITING